(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 85.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Bridgebio Pharma's revenue in 2026 is $353,780,000.On average, 22 Wall Street analysts forecast BBIO's revenue for 2026 to be $175,667,572,666, with the lowest BBIO revenue forecast at $109,535,689,309, and the highest BBIO revenue forecast at $250,714,165,713. On average, 19 Wall Street analysts forecast BBIO's revenue for 2027 to be $302,552,836,410, with the lowest BBIO revenue forecast at $207,740,100,414, and the highest BBIO revenue forecast at $363,256,112,505.
In 2028, BBIO is forecast to generate $441,110,472,957 in revenue, with the lowest revenue forecast at $347,839,407,465 and the highest revenue forecast at $598,746,281,991.